Temperature-dependent irreversible conformational change of recombinant ADAMTS13 upon metal ion chelation

J Thromb Haemost. 2019 Jun;17(6):995-1002. doi: 10.1111/jth.14440. Epub 2019 Apr 21.

Abstract

Background: The catalytic domain of ADAMTS13 possesses one Zn2+ and up to three putative Ca2+ binding sites and can be inactivated by chelating agents. Although replenishment with an appropriate metallic cation is thought to restore the enzyme's proteolytic activity fully, ADAMTS13 stability in a metal ion-depleting environment has not been explored.

Objectives: To address the stability of ADAMTS13 in citrated human plasma.

Methods: ADAMTS13 activity was measured using the FRETS-VWF73 fluorogenic assay. The molar ratio of metals bound to ADAMTS13 was determined by size exclusion chromatography inductively coupled plasma mass spectrometry (SEC-ICP-MS). Higher-order structural changes were analyzed using Fourier-transformed infrared spectroscopy and dynamic light scattering.

Results: ADAMTS13 was stable at room temperature for up to 24 hours irrespective of the presence of citrate (0.38%). However, at 37°C, citrate caused a time-dependent activity decrease. No ADAMTS13 activity decrease was seen in heparinized plasma, but the addition of citrate again caused ADAMTS13 instability at 37°C. Scavenging of citrate by the addition of Ca2+ or Zn2+ prior to but not postincubation prevented the activity decrease of the enzyme. The SEC-ICP-MS analyses showed that ADAMTS13 only bound Zn2+ and that its reduced activity correlated with a gradual loss of bound Zn2+ . Concomitant higher-order structural analyses demonstrated structural changes in ADAMTS13 that are typical of less-ordered protein structures.

Conclusions: Zn2+ is required to stabilize ADAMTS13 structure at physiologic temperature, thereby preventing irreversible loss of enzyme activity. This finding is particularly important to consider when using citrated human plasma as a source of ADAMTS13 in clinical settings.

Keywords: ADAMTS13 protein; blood plasma; protein conformation; protein stability; zinc.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADAMTS13 Protein / antagonists & inhibitors
  • ADAMTS13 Protein / chemistry*
  • ADAMTS13 Protein / metabolism
  • Calcium / metabolism
  • Catalytic Domain / drug effects
  • Chelating Agents / pharmacology
  • Citric Acid / pharmacology
  • Dynamic Light Scattering
  • Enzyme Stability / drug effects
  • Fluorescence Resonance Energy Transfer
  • Humans
  • In Vitro Techniques
  • Mass Spectrometry
  • Protein Conformation / drug effects
  • Purpura, Thrombotic Thrombocytopenic / blood
  • Purpura, Thrombotic Thrombocytopenic / drug therapy
  • Recombinant Proteins / chemistry
  • Recombinant Proteins / metabolism
  • Recombinant Proteins / therapeutic use
  • Spectroscopy, Fourier Transform Infrared
  • Temperature
  • Zinc / metabolism

Substances

  • Chelating Agents
  • Recombinant Proteins
  • Citric Acid
  • ADAMTS13 Protein
  • ADAMTS13 protein, human
  • Zinc
  • Calcium